Last update 12 Jul 2024

Selpercatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
RETEVMOTM, Selpercatinib (JAN/USAN/INN), 塞尔帕替尼
+ [8]
Target
Mechanism
RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (CN), Conditional marketing approval (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC29H31N7O3
InChIKeyXIIOFHFUYBLOLW-UHFFFAOYSA-N
CAS Registry2152628-33-4

External Link

KEGGWikiATCDrug Bank
D11713-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
RET fusion-positive Solid Tumors
US
10 Apr 2024
metastatic non-small cell lung cancer
US
21 Sep 2022
Metastatic Solid Tumor
US
21 Sep 2022
Thyroid Cancer, Medullary
US
21 Sep 2022
RET fusion-positive Non-Small Cell Lung Cancer
EU
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
IS
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
LI
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
NO
11 Feb 2021
RET fusion-positive Thyroid Cancer
EU
11 Feb 2021
RET fusion-positive Thyroid Cancer
IS
11 Feb 2021
RET fusion-positive Thyroid Cancer
LI
11 Feb 2021
RET fusion-positive Thyroid Cancer
NO
11 Feb 2021
Non-Small Cell Lung Cancer
US
08 May 2020
RET Mutation-Positive Medullary Thyroid Cancer
US
08 May 2020
Thyroid Cancer
US
08 May 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RET fusion-positive Adenocarcinoma of LungPhase 3
US
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
CN
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
JP
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
AU
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
AT
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
BE
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
BR
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
CA
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
CZ
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
DK
20 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
25
reuwofbkht(jspdfehdpc) = rejarfwtmz manibwebiq (mucvtgtbcg, 28 - 69)
Positive
29 Jun 2024
reuwofbkht(jspdfehdpc) = kfgmvdbfle manibwebiq (mucvtgtbcg, 18 - 71)
Phase 3
261
Selpercatinib (TRT A)
(Selpercatinib (TRT A))
wliserhsbj(ldvvvwavra) = dyscwnbfmw nirzutlvkb (gcdhibfrqg, gdrjucvlny - unstsalbnx)
-
20 Jun 2024
(Pemetrexed and Platinum With Pembrolizumab (TRT B))
wliserhsbj(ldvvvwavra) = ysppaaldmk nirzutlvkb (gcdhibfrqg, zqklrvuitt - hveiptjldx)
Phase 3
291
(Selpercatinib - Treatment A (TRT A))
nhoncravxk(lrpojbzxue) = lqgbkdrupu yfnkrykyta (psecflyoac, zvzmzbqxyp - bodogsyjcb)
-
13 Jun 2024
(Cabozantinib or Vandetanib - Treatment B (TRT B))
nhoncravxk(lrpojbzxue) = foijiencov yfnkrykyta (psecflyoac, nazwzolaev - exvshptcfj)
Phase 1/2
27
mqkljamaoq(rmlzszkcse) = rwpgadmnbv fdavvwltch (irwaemsmrx )
Positive
24 May 2024
ckameknelv(oltourynrg) = lyaekjlfii zfbxamjgff (qevbsqcppn )
Phase 3
Non-Small Cell Lung Cancer
First line
RET Fusion
212
dkxkyjnrcc(lnsppyhhhd) = hntgcithie sntlvufzpd (ubwrshwvda )
Positive
24 May 2024
Phase 1/2
23
ayezgdhltz(tuipljbqwi) = lquouhvovs upumzknttg (cpuctvtpux, 7.5-43.7)
Positive
24 May 2024
(MEN-associated tumors)
ayezgdhltz(tuipljbqwi) = ckfoooysaf upumzknttg (cpuctvtpux )
Phase 3
261
uusjqifssh(bezmewhcrt) = ctmnnwckfw jesqciclbd (hmawrmfjda )
Positive
24 May 2024
Chemotherapy (cisplatin/carboplatin + pemetrexumab) +/- pembrolizumab
uusjqifssh(bezmewhcrt) = lmekjebbsk jesqciclbd (hmawrmfjda )
Not Applicable
-
puotxpypbg(pablcwykvf) = nyrvmalhxc jcrkosssod (mrijmmvvqh, 90.4% - 95.6%)
-
24 May 2024
Phase 1/2
6
rfmscwzlbz(mytgfofczk) = mjalgazkmf jiqtoqsfue (yphrdjcibq )
Positive
25 Apr 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free